Consider a patient with a fasting glucose of 94 mg/dL and a fasting insulin of 18 µIU/mL. Both values fall within their laboratory's reference range. The standard interpretation: normal. The more complete interpretation: a HOMA-IR of 4.2 — well above the threshold associated with significant insulin resistance — in a person whose glucose is still normal only because the pancreas is working considerably harder than it should.
This is the gap that fasting insulin, interpreted in context, is designed to close. It is one of the earliest detectable signals of metabolic dysfunction — often appearing years, sometimes a decade, before fasting glucose or HbA1c move out of their standard reference ranges. And it has meaningful implications not just for diabetes prevention, but for cardiovascular health and healthy longevity.
## What Is Fasting Insulin? Fasting insulin is a blood test that measures the concentration of insulin in your bloodstream after an overnight fast — typically 8 to 12 hours without caloric intake. Insulin is the hormone produced by the beta cells of the pancreas whose primary role is to facilitate glucose uptake by muscle, liver, and fat cells. In a metabolically healthy person, a modest amount of insulin is sufficient to keep fasting glucose in a normal range. As insulin resistance develops, the same cells become progressively less responsive to insulin's signal, and the pancreas compensates by producing more — keeping fasting glucose "normal" while the underlying problem silently worsens. This compensatory hyperinsulinemia is exactly what a fasting insulin test can detect: not yet a glucose problem, but already an insulin problem.
Why this matters for cardiovascular risk: Elevated fasting insulin is independently associated with hypertension, dyslipidemia (particularly elevated triglycerides and low HDL), endothelial dysfunction, and increased risk of atherosclerotic cardiovascular disease — all before diabetes develops. Chronically elevated insulin also promotes atherogenic lipid patterns, including the small, dense LDL particle phenotype discussed in ApoB: The Complete Guide.
## What Is "Normal" vs. "Optimal" Fasting Insulin? Most clinical laboratory reference ranges for fasting insulin extend to approximately 24–25 µIU/mL — a threshold derived from the statistical distribution of the general population, not from the metabolic characteristics associated with optimal long-term health. In a population where insulin resistance is highly prevalent, a reference range built from that population will reflect the norm rather than the optimum. Longevity-oriented and metabolic health frameworks generally use considerably tighter targets:
| Fasting Insulin (µIU/mL) | Interpretation | Clinical Context |
|---|---|---|
| < 5 | Optimal | Excellent insulin sensitivity; consistent with longevity-oriented metabolic health targets |
| 5–10 | Acceptable — monitor | Generally within a healthy range; worth tracking alongside glucose, triglycerides, and waist circumference |
| 10–15 | Early signal — investigate | Suggests early compensatory hyperinsulinemia; warrants a closer look at full metabolic picture even if glucose is normal |
| > 15–25 | Elevated — act | Consistent with established insulin resistance in a longevity context, regardless of lab "normal" label; calculate HOMA-IR |
These ranges reflect longevity-oriented clinical interpretation and may differ from your laboratory's reference range. Always interpret in clinical context with your physician.
## HOMA-IR: Combining Fasting Insulin and Glucose Fasting insulin alone is informative, but its clinical meaning depends substantially on what is happening with glucose at the same time. HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) brings the two together into a single calculated index that quantifies how much insulin the body is requiring to maintain its current fasting glucose level. ### The Formula
HOMA-IR Formula
If glucose is reported in mmol/L: divide by 22.5 instead of 405
Both fasting insulin and fasting glucose must be from the same blood draw, after 8–12 hours of fasting.
| HOMA-IR Score | Interpretation | Clinical Implication |
|---|---|---|
| < 1.0 | Optimal | Excellent insulin sensitivity; associated with favorable longevity metabolic profile |
| 1.0–1.9 | Normal range — acceptable | Within conventional normal; monitor with other metabolic markers |
| 1.9–2.9 | Early insulin resistance | Warrants lifestyle intervention; review diet, activity, waist circumference, triglycerides |
| > 2.9 | Significant insulin resistance | Consistent with established metabolic dysfunction; clinical assessment recommended |
Important limitation: HOMA-IR cut-offs vary between studies and populations. A HOMA-IR of 1.4 has been proposed as a dysglycaemia threshold in some Asian population cohorts, while Western studies have generally used higher thresholds. These values are best used as trend markers and relative risk guides rather than absolute diagnostic cutoffs — always interpret alongside clinical context.
## Reading the Pattern: Insulin and Glucose Together The most clinically useful interpretation of fasting insulin comes from understanding the relationship between insulin and glucose — not either number in isolation.
See it for your own number. The free Optimal vs Normal check puts your fasting insulin, HOMA-IR and glucose next to both your lab's standard range and the longevity-optimal targets a lipidologist works from — no sign-up, and your numbers stay in your browser.
Low insulin + normal glucose
The most favorable pattern. Cells respond efficiently to insulin; the pancreas doesn't need to overproduce. Generally consistent with good metabolic health and insulin sensitivity.
High insulin + normal glucose
Early compensatory hyperinsulinemia. Glucose looks fine — but only because the pancreas is working harder than it should. This is the pattern HOMA-IR and fasting insulin testing are specifically designed to detect.
High insulin + elevated glucose
More established metabolic dysfunction. The pancreas can no longer fully compensate; glucose is now rising despite elevated insulin. This pattern suggests prediabetes or type 2 diabetes territory.
## Fasting Insulin, Longevity, and Cardiovascular Risk The connection between insulin resistance and lifespan is one of the more robust findings in aging biology. Studies of long-lived families — individuals with exceptional longevity and their offspring — consistently show enhanced insulin sensitivity and lower fasting insulin compared with age-matched controls. Centenarian cohorts have been observed to maintain normal glucose tolerance with relatively low fasting insulin even in advanced age, suggesting that efficient insulin handling may be a characteristic feature, not merely a consequence, of healthy aging. The mechanisms connecting chronic hyperinsulinemia to accelerated aging and cardiovascular risk are multiple. Elevated insulin promotes hepatic production of triglyceride-rich VLDL particles — directly contributing to the atherogenic dyslipidemia pattern (elevated triglycerides, low HDL, small dense LDL) that ApoB testing is particularly well-suited to detect. It also promotes visceral adiposity, systemic inflammation, endothelial dysfunction, and — through its interaction with IGF-1 signaling — influences cellular aging pathways at a fundamental level. This is why fasting insulin occupies a different position in longevity-oriented cardiovascular assessment than in standard diabetes screening. The question is not just "does this person have diabetes?" but "is this person's metabolic machinery operating efficiently, in a way consistent with long-term cardiovascular and cellular health?"
## Practical Interpretation: What to Do with Your Result ### Testing Conditions Matter A standard overnight fast of 8–12 hours is preferred for fasting insulin testing because it gives the most interpretable and reproducible baseline. Shorter fasts may leave insulin influenced by recent food intake — particularly from high-carbohydrate or high-fat meals. Very prolonged fasting can suppress insulin below its true fasting baseline. Stress, poor sleep, acute illness, and strenuous exercise in the preceding 24 hours can all transiently influence insulin levels. For this reason, fasting insulin is best interpreted as a pattern marker tracked over time and across consistent conditions, rather than as a single definitive measurement. ### What to Measure Alongside It Fasting insulin and HOMA-IR do not stand alone. The most clinically useful metabolic picture combines: - **Fasting glucose** — required for HOMA-IR calculation; together these reveal the insulin-glucose relationship - **HbA1c** — reflects average glucose over the preceding 2–3 months; catches dysglycaemia that a single fasting glucose might miss - **Triglycerides** — elevated triglycerides are closely linked to insulin resistance and hepatic lipoprotein overproduction - **HDL cholesterol** — typically falls as insulin resistance rises; low HDL with high triglycerides is a classical insulin-resistance pattern - **Waist circumference** — visceral adiposity is the strongest anthropometric correlate of insulin resistance - **ApoB** — captures the atherogenic particle burden that insulin resistance tends to drive, even when LDL-C looks acceptable ### When to Act If fasting insulin is above 10 µIU/mL or HOMA-IR is above 1.9 — even with normal glucose — a targeted review of diet quality (particularly refined carbohydrates and added sugars), physical activity, sleep quality, and waist circumference is a clinically appropriate first response. These are the modifiable factors most consistently shown to improve insulin sensitivity, often substantially, before pharmacological intervention is needed.
## Common Questions
Yes — this is one of the central points of this article. Standard laboratory reference ranges for fasting insulin extend to approximately 24–25 µIU/mL in most labs, but longevity and metabolic health frameworks generally consider values above 10 µIU/mL worth investigating, and values above 15 µIU/mL a clear signal for further assessment — even when the result is labelled "normal" on the report.
You need two values from the same fasting blood draw: fasting insulin (in µIU/mL) and fasting glucose (in mg/dL). Multiply them together, then divide by 405. If your glucose is in mmol/L, divide by 22.5 instead. A result below 1.0 is generally considered optimal; above 1.9 suggests early insulin resistance; above 2.9 suggests more established insulin resistance.
Elevated HOMA-IR is independently associated with hypertension, dyslipidemia, endothelial dysfunction, and increased cardiovascular event risk — beyond its well-established association with diabetes progression. The atherogenic dyslipidemia pattern driven by insulin resistance (elevated triglycerides, low HDL, small dense LDL) is one of the key mechanisms linking insulin resistance to cardiovascular risk, which is why ApoB testing is particularly informative in people with elevated fasting insulin or HOMA-IR.
Yes — insulin sensitivity is one of the most modifiable metabolic parameters. Reducing refined carbohydrates and added sugars, increasing aerobic and resistance exercise, reducing visceral adiposity, improving sleep quality, and managing chronic stress all have consistent evidence for improving fasting insulin and HOMA-IR. The earlier these interventions begin — ideally before glucose itself rises — the more room there is for meaningful improvement.
No. Diabetes is diagnosed using fasting glucose, HbA1c, or an oral glucose tolerance test (OGTT) — not fasting insulin. Fasting insulin is not a diagnostic test for diabetes; it is a marker of insulin resistance and metabolic efficiency, which is most useful for identifying risk and metabolic patterns before diabetes develops.
See Your Full Cardiometabolic Picture with CardioIQ
Fasting insulin, ApoB, Lp(a), triglycerides, and HbA1c together tell a story that no single marker can tell alone. CardioIQ analyzes your full panel and generates a guideline-anchored clinical interpretation.
Important Medical Notice. This article is for educational and informational purposes only. Reference ranges and thresholds cited reflect longevity-oriented clinical interpretation and may differ from standard laboratory reference ranges. This content does not constitute medical diagnosis or treatment advice, and does not replace the judgment of a licensed healthcare professional. Always consult a qualified physician before making decisions about your health or treatment.
References
- Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419. doi:10.1007/BF00280883
- So WY, et al. Optimal Cut-Offs of HOMA-IR to Identify Dysglycemia and T2DM: A 15-Year Prospective Study. PMC. PMC5033570
- Bonora E, et al. Prevalence of insulin resistance in metabolic disorders (Bruneck Study). Diabetes. 1998;47(10):1643–1649.
- Paolisso G, et al. Metabolic features of healthy centenarians: insulin action and insulin secretion. Aging Clinical and Experimental Research. 2007.
- Lamkin Clinic. HOMA-IR: Optimal Levels, Reference Ranges and Insulin Resistance Interpretation. 2026. lamkinclinic.com/homa-ir
- Superpower. HOMA-IR: Calculation, Score Ranges and What It Means for You. superpower.com